180 related articles for article (PubMed ID: 25780477)
1. The efficacy of vildagliptin concomitant with insulin therapy in type 2 diabetic subjects.
Ito D; Inoue K; Kaneko K; Yanagisawa M; Sumita T; Ikegami Y; Awata T; Ishida H; Katayama S; Inukai K
J Clin Med Res; 2015 May; 7(5):303-7. PubMed ID: 25780477
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of vildagliptin, sitagliptin, and linagliptin as add-on therapy in Chinese patients with T2DM inadequately controlled with dual combination of insulin and traditional oral hypoglycemic agent.
Tang YZ; Wang G; Jiang ZH; Yan TT; Chen YJ; Yang M; Meng LL; Zhu YJ; Li CG; Li Z; Yu P; Ni CL
Diabetol Metab Syndr; 2015; 7():91. PubMed ID: 26500706
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of vildagliptin and sitagliptin determined by continuous glucose monitoring in patients with type 2 diabetes mellitus.
Koyanagawa N; Miyoshi H; Ono K; Nakamura A; Cho KY; Yamamoto K; Takano Y; Dan-Noura M; Atsumi T
Endocr J; 2016 Aug; 63(8):747-53. PubMed ID: 27321385
[TBL] [Abstract][Full Text] [Related]
4. A Randomized Controlled Trial of Vildagliptin Versus Alogliptin: Effective Switch From Sitagliptin in Patients With Type 2 Diabetes.
Shigematsu E; Yamakawa T; Oba MS; Suzuki J; Nagakura J; Kadonosono K; Terauchi Y
J Clin Med Res; 2017 Jul; 9(7):567-572. PubMed ID: 28611856
[TBL] [Abstract][Full Text] [Related]
5. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
[TBL] [Abstract][Full Text] [Related]
6. Vildagliptin vs liraglutide as a second-line therapy switched from sitagliptin-based regimens in patients with type 2 diabetes: A randomized, parallel-group study.
Takeshita Y; Takamura T; Kita Y; Otoda T; Kato K; Wakakuri H; Yamada M; Misu H; Matsushima Y; Kaneko S;
J Diabetes Investig; 2015 Mar; 6(2):192-200. PubMed ID: 25802727
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of DPP4 Inhibitor and Basal Insulin in Type 2 Diabetes: An Updated Review and Challenging Clinical Scenarios.
Gomez-Peralta F; Abreu C; Gomez-Rodriguez S; Barranco RJ; Umpierrez GE
Diabetes Ther; 2018 Oct; 9(5):1775-1789. PubMed ID: 30117055
[TBL] [Abstract][Full Text] [Related]
8. Predictive clinical parameters and glycemic efficacy of vildagliptin treatment in korean subjects with type 2 diabetes.
Chang JS; Shin J; Kim HS; Kim KH; Shin JA; Yoon KH; Cha BY; Son HY; Cho JH
Diabetes Metab J; 2013 Feb; 37(1):72-80. PubMed ID: 23439802
[TBL] [Abstract][Full Text] [Related]
9. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients.
Derosa G; Bonaventura A; Bianchi L; Romano D; Fogari E; D'Angelo A; Maffioli P
Metabolism; 2014 Jul; 63(7):957-67. PubMed ID: 24874591
[TBL] [Abstract][Full Text] [Related]
10. Continuous glucose profiles with vildagliptin versus sitagliptin in add-on to metformin: results from the randomized Optima study.
Guerci B; Monnier L; Serusclat P; Petit C; Valensi P; Huet D; Raccah D; Colette C; Quéré S; Dejager S
Diabetes Metab; 2012 Oct; 38(4):359-66. PubMed ID: 22809630
[TBL] [Abstract][Full Text] [Related]
11. Clinical evidence and mechanistic basis for vildagliptin's action when added to metformin.
Ahrén B; Foley JE; Bosi E
Diabetes Obes Metab; 2011 Mar; 13(3):193-203. PubMed ID: 21205107
[TBL] [Abstract][Full Text] [Related]
12. Beneficial Effects of Vildagliptin on Metabolic Parameters in Patients with Type 2 Diabetes.
Shimodaira M; Niwa T; Nakajima K; Kobayashi M
Endocr Metab Immune Disord Drug Targets; 2015; 15(3):223-8. PubMed ID: 25809193
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and Safety of Vildagliptin as an Add-On Therapy in Inadequately Controlled Type 2 Diabetes Patients Treated With Basal Insulin.
Saito D; Kanazawa A; Shigihara N; Sato F; Uchida T; Sato J; Goto H; Miyatsuka T; Ikeda F; Ogihara T; Ohmura C; Watada H
J Clin Med Res; 2017 Mar; 9(3):193-199. PubMed ID: 28179966
[TBL] [Abstract][Full Text] [Related]
14. Hypoglycemia hospitalization frequency in patients with type 2 diabetes mellitus: a comparison of dipeptidyl peptidase 4 inhibitors and insulin secretagogues using the French health insurance database.
Detournay B; Halimi S; Robert J; Deschaseaux C; Dejager S
Vasc Health Risk Manag; 2015; 11():417-25. PubMed ID: 26229480
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness, safety, and tolerability of vildagliptin or vildagliptin/metformin combination in patients with type 2 diabetes uncontrolled on insulin therapy in a real-world setting in Egypt: The OMEGA study.
El Ebrashy I; El Kafrawy N; Raouf R; Yousry D
Diabetes Res Clin Pract; 2020 Apr; 162():108042. PubMed ID: 32006641
[TBL] [Abstract][Full Text] [Related]
16. Medium-Term Effect of Add-On Therapy with the DPP-4 Inhibitor, Sitagliptin, in Insulin-Treated Japanese Patients with Type 2 Diabetes Mellitus.
Katsuno T; Ikeda H; Namba M
Diabetes Ther; 2016 Jun; 7(2):309-20. PubMed ID: 27114254
[TBL] [Abstract][Full Text] [Related]
17. Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin.
Kim JH; Kim SS; Baek HS; Lee IK; Chung DJ; Sohn HS; Bae HY; Kim MK; Park JH; Choi YS; Kim YI; Hahm JR; Lee CW; Jo SR; Park MK; Lee KJ; Kim IJ
Diabetes Metab J; 2016 Jun; 40(3):230-9. PubMed ID: 27098505
[TBL] [Abstract][Full Text] [Related]
18. Effects of vildagliptin as add-on treatment in patients with type 2 diabetes mellitus: insights from long-term clinical studies in Japan.
Odawara M; Sagara R
J Diabetes Metab Disord; 2015; 15():21. PubMed ID: 27382546
[TBL] [Abstract][Full Text] [Related]
19. Vildagliptin: a novel oral therapy for type 2 diabetes mellitus.
Lauster CD; McKaveney TP; Muench SV
Am J Health Syst Pharm; 2007 Jun; 64(12):1265-73. PubMed ID: 17563048
[TBL] [Abstract][Full Text] [Related]
20. Add-on treatment with mitiglinide improves residual postprandial hyperglycemia in type 2 diabetic patients receiving the combination therapy with insulin glargine and sitagliptin.
Murakami T; Nambu T; Kato T; Matsuda Y; Yonemitsu S; Muro S; Oki S
Tohoku J Exp Med; 2015 Apr; 235(4):255-60. PubMed ID: 25810423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
